News
Synthes and Lilly Sign Development and Collaboration Agreement
Synthes, Inc. and Eli Lilly and Company announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures. ...
News
Kuecept present at Procept Spray Drying seminar in Barcelona
Kuecept were pleased to be invited to present their latest research in the field of spray drying at the Procept Spray Drying Seminar held in Barcelona on the 8th June. With over 50 attendees from more than 15 organisations...
News
Biogen Idec Receives Approval in the European Union for AVONEX(R) PEN
Biogen Idec announced that the European Commission (EC) has granted approval to AVONEX PEN for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event. Douglas E. Williams, Ph.D.,...
News
Dr. Reddy’s announces three generic product launches in the US Market
Dr. Reddy’s Laboratories announced that it has launched the following three products in the US market: Donepezil Hydrochloride tablets (5mg and 10mg strengths), a bioequivalent generic version of ARICEPT® tablets*. The Food & Drug Administration (FDA)...
News
Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement
Bristol-Myers Squibb Company announced it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb’s CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche’s investigational oral BRAF inhibitor, vemurafenib, in treating patients with...
News
Cytokinetics to Present Clinical Data Relating to CK-2017357
Cytokinetics, Incorporated announced that two posters relating to CK-2017357 are scheduled to be presented at the 22nd Annual Sessions of the Society for Vascular Medicine to be held June 2-4, 2011 at the Seaport Hotel in Boston, MA. ...
News
AstraZeneca signs agreement in Japan with Daiichi Sankyo
AstraZeneca announced a co-promotion agreement in Japan with Daiichi Sankyo for denosumab for the treatment of bone disorders stemming from bone metastasis. AstraZeneca and Daiichi Sankyo will co-promote denosumab after it is approved for use in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.